Crispr Surges as Gene Editing Shows Promise in Blood Disease

(Bloomberg) -- A first-in-human study using the gene-editing tool Crispr has a company named after the technology and its partner, Vertex Pharmaceuticals Inc., claiming an early victory in treating...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.